Opendata, web and dolomites

FutureTrophicFactors SIGNED

Elucidating therapeutic effects and mode of action of future trophic factorsin ALS and Parkinson’s disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 FutureTrophicFactors project word cloud

Explore the words cloud of the FutureTrophicFactors project. It provides you a very rough idea of what is the project "FutureTrophicFactors" about.

secretary    treatments    administered    relieve    culture    regulate    human    symptoms    drawbacks    pluripotent    discovery    disease    trials    neurodegenerative    survival    invasive    rodent    stop    vitro    toxin    restores    model    understand    brain    parkinson    drugs    innovative    overcome    prevalence    direct    progression    nerve    function    mode    animal    protects    action    treat    ohda    population    ultimate    poor    difficulty    protein    neurite    subcutaneously    neurorestorative    patients    fragment    pd    barrier    cdnf    efficacy    penetrating    therapies    neurotrophic    ntfs    als    cell    effect    bbb    da    data    treatment    despite    peptides    motor    polypeptides    expectancy    showed    blood    measured    monkey    life    groundbreaking    models    urgent    surgery    ips    aging    lateral    therapeutic    enters    ntf    treating    explored    sclerosis    amyotrophic    proteins    vivo    pass    diseases    peripheral    branching    cultures    clinical    variant    dopamine    neurons    rhesus    stem    trophic    cells   

Project "FutureTrophicFactors" data sheet

The following table provides information about the project.

Coordinator
HELSINGIN YLIOPISTO 

Organization address
address: YLIOPISTONKATU 3
city: HELSINGIN YLIOPISTO
postcode: 14
website: www.helsinki.fi

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Finland [FI]
 Total cost 1˙497˙597 €
 EC max contribution 1˙497˙597 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-STG
 Funding Scheme ERC-STG
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2024-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HELSINGIN YLIOPISTO FI (HELSINGIN YLIOPISTO) coordinator 1˙497˙597.00

Map

 Project objective

The prevalence of neurodegenerative diseases such as Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS) is growing rapidly due to an aging population and increased life expectancy. Current treatments for ALS and PD only relieve symptoms and cannot stop the progression of the disease, thus there is an urgent need for new therapies. Neurotrophic factors (NTFs) are secretary proteins that regulate the survival of neurons, neurite growth and branching. They have been explored as novel drugs for the treatment of ALS and PD but their efficacy in clinical trials is poor. CDNF is a protein with NTF properties that protects and restores the function of dopamine neurons in rodent and rhesus monkey toxin models of PD more effectively than other NTFs. CDNF is currently in phase 1/2 clinical trials on PD patients. Despite promising results with CDNF in animal models of PD, NTF and CDNF-based treatments have drawbacks. CDNF requires direct delivery to the brain through invasive surgery since, it cannot pass through the blood brain barrier (BBB). My recent discovery, however, may overcome this difficulty: I showed that a novel CDNF variant protects DA neurons in vitro and in vivo and that it efficiently enters DA neurons in culture. Furthermore, my data show the CDNF fragment can pass through the BBB as measured by 3 different methods and has a neurorestorative effect in a 6-OHDA toxin model of PD when administered subcutaneously. The ultimate goal of my research is to understand the mode of action and therapeutic effect of novel BBB penetrating CDNF-derived polypeptides in cultures of human induced pluripotent stem (iPS) cell-derived nerve cells from patients and in animal models of ALS and PD. The innovative aspect of this proposal is the new groundbreaking concept for treating neurodegenerative diseases – peripheral delivery of BBB penetrating peptides with trophic factor properties and the potential to treat non-motor and motor symptoms in ALS and PD patients.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FUTURETROPHICFACTORS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FUTURETROPHICFACTORS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

MOCHA (2019)

Understanding and leveraging ‘moments of change’ for pro-environmental behaviour shifts

Read More  

SWIP (2019)

Extended short-wave infrared pulsed fibre laser

Read More  

ChaperoneRegulome (2020)

ChaperoneRegulome: Understanding cell-type-specificity of chaperone regulation

Read More